Endotoxin Detection Solutions for Biopharmaceuticals

2025-10-09

Endotoxin Detection Solutions for Biopharmaceuticals

BETMATProject Background and Core Challenges

Biopharmaceuticals refer to drugs produced by means of biotechnology such as genetic engineering and cell engineering, including monoclonal antibodies, recombinant proteins, vaccines, cell therapy products, blood products, etc. These drugs act directly on the human immune system or blood circulatory system, and their sensitivity to endotoxin contamination is much higher than that of chemical drugs. Even an endotoxin dose of 0.1 EU/kg may cause severe adverse reactions such as fever, anaphylactic shock, and even multiple organ failure.

Compared with pharmaceutical water, endotoxin detection of biopharmaceuticals faces three core challenges: ① The sample composition is complex, containing high-concentration proteins (e.g., monoclonal antibody concentration up to 100 mg/ml), surfactants (e.g., polysorbate 80), buffer salts (e.g., Tris, phosphate), etc., which are likely to interfere with the Limulus Amebocyte Lysate (LAL) reaction; ② The endotoxin limits vary greatly among different varieties (e.g., vaccines usually ≤ 10 EU/dose, monoclonal antibodies ≤ 0.5 EU/mg), requiring high-sensitivity detection methods; ③ Some biopharmaceuticals (e.g., cell therapy products) are unstable and cannot withstand pretreatment such as high temperature and extreme pH, which increases the difficulty of interference elimination.

In accordance with pharmacopoeia standards, this solution provides a solution for "method validation - sample processing - detection implementation - quality control" based on the characteristics of biopharmaceuticals to ensure the accuracy, compliance, and reliability of detection results.

Endotoxin Detection Solutions for Biopharmaceuticals

Endotoxin Limit Setting and Standard Basis for Biopharmaceuticals

The endotoxin limit of biopharmaceuticals should be set in accordance with the route of administration, dosage, clinical use of the drug, and the guidelines of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) Q6B. The core calculation formula is as follows:

L = K/M

Where: L is the endotoxin limit (EU/ml or EU/mg); K is the maximum tolerable endotoxin dose per kilogram of body weight per hour (for intravenous administration, K = 5 EU/kg·h; for intrathecal administration, K = 0.2 EU/kg·h); M is the maximum dose of the drug administered per kilogram of body weight per hour (ml/kg·h or mg/kg·h).

Endotoxin Limits and Standard Requirements for Common Biopharmaceuticals

Drug Category	Representative Products	Endotoxin Limit Requirement	Route of Administration
Monoclonal Antibodies	Pembrolizumab	≤ 0.5-2 EU/mg	Intravenous Injection, Subcutaneous Injection
Recombinant Proteins	Recombinant Human Insulin, Growth Hormone	≤ 0.01-0.1 EU/U	Subcutaneous Injection, Intravenous Injection
Vaccines	Inactivated COVID-19 Vaccine, Hepatitis B Vaccine	≤ 1-10 EU/dose	Intramuscular Injection, Subcutaneous Injection
Blood Products	Human Serum Albumin, Immunoglobulin	≤ 0.5 EU/ml	Intravenous Injection
Cell Therapy Products	CAR-T Cell Preparations	≤ 0.06 EU/kg of Patient's Body Weight	Intravenous Infusion

Note: "Dose" refers to the single administration dose, and "U" refers to the biological activity unit. The specific limit should be confirmed in combination with the drug label and registration approval requirements.

Selection of Detection Methods and Compatibility Analysis

The endotoxin detection of biopharmaceuticals still mainly relies on the pharmacopoeia-approved gel-clot method, photometric method (turbidimetric method/chromogenic method), but the compatible method should be selected according to the sample characteristics (e.g., protein concentration, interference degree, sensitivity requirement). In recent years, the recombinant factor C (rFC) method has been increasingly used in the detection of biopharmaceuticals due to its strong anti-interference ability and high specificity.

Compatibility Comparison of Three Core Methods

Detection Method	Core Principle	Advantages	Limitations	Compatible Biopharmaceutical Types
Gel-Clot Method	The reaction between LAL and endotoxin forms a gel	① Simple operation; ② No special equipment required	① Inability to accurately quantify, only applicable for limit testing	Endotoxin limit detection of final products before release
Chromogenic Method	The hydrolysis of chromogenic substrate produces colored products	① Capable of quantification, facilitating trend analysis; ② Strong anti-interference ability	① High cost of instruments and reagents	Detection of products such as monoclonal antibodies and recombinant proteins (requiring pretreatment to eliminate interference)
rFC Method	recombinant Limulus reagent that reacts with endotoxin	① High specificity (only reacts with endotoxin, not with glucan); ② No dependence on animal resources	① Not yet recognized by some pharmacopoeias	Samples that may contain glucan, cell therapy products (the feasibility of the method needs to be verified)

Selection of Detection Methods

Step 1: Clarify the detection purpose

● For "compliance limit testing": Prioritize the gel-clot method or chromogenic method;

● For "quantitative monitoring in the production process": Prioritize the chromogenic method or rFC method;

● For "samples containing glucan": Prioritize the rFC method.

Step 2: Evaluate the degree of sample interference

● Low interference (protein concentration < 10 mg/ml, no surfactants): Gel-clot method or chromogenic method;

● Medium to high interference (protein concentration 10-100 mg/ml, containing polysorbate): Chromogenic method (requiring pretreatment);

● Extremely high interference (protein concentration > 100 mg/ml, containing complex excipients): rFC method.

Step 3: Match the sensitivity requirement

● Limit ≤ 0.1 EU/ml: Select the chromogenic method (detection limit 0.001 EU/ml) or rFC method;

● Limit > 0.1 EU/ml: The gel-clot method can meet the requirement.

features

Key Technology: Sample Pretreatment and Interference Elimination

Interference from proteins and excipients in biopharmaceuticals is the main cause of detection failure. Pretreatment is required to eliminate interference, and the core principle is to "retain endotoxin activity and remove/dilute interfering substances".

Common Pretreatment Methods and Applicable Scenarios

Pretreatment Method	Principle	Operational Steps	Applicable Sample Types	Precautions
Dilution Method	Reduce the concentration of interfering substances to a non-interfering level	Dilute the sample with LAL Reagent Water to a protein concentration < 10 mg/ml, ensuring that the endotoxin concentration after dilution is still within the range of the standard curve	Samples with medium to low protein concentrations (e.g., recombinant insulin)	The dilution factor needs to be verified (recovery rate 50%-200%)
Protein Precipitation Method	Precipitate proteins with strong acid/organic solvents	1. Mix the sample with 10% trichloroacetic acid at a ratio of 1:1 and let it stand at 4°C for 30 minutes; 2. Centrifuge at 10,000 r/min for 10 minutes; 3. Take the supernatant for detection	High-concentration monoclonal antibodies, blood products	Avoid excessive centrifugation leading to endotoxin precipitation
Ultrafiltration Method	Ultrafiltration membrane retains proteins, while endotoxin passes through	1. Add the sample to a 30 kDa endotoxin-free ultrafiltration centrifuge tube; 2. Centrifuge at 4,000 r/min for 15 minutes; 3. Collect the filtrate for detection	Macromolecular protein samples (e.g., monoclonal antibodies with a molecular weight > 50 kDa)	Rinse the ultrafiltration membrane with LAL Reagent Water 3 times in advance
Adding Interference Inhibitors	Inhibitors combine with interfering substances to release endotoxin	Add an interference inhibitor (e.g., polyethylene glycol 6000) to the reaction system to a final concentration of 0.5%-1%	Samples containing surfactants (e.g., vaccines containing Tween 80)	It is necessary to verify that the inhibitor has no impact on the reaction between LAL and endotoxin
Chromatographic Purification Method	Remove proteins by affinity chromatography	Adsorb endotoxin with an endotoxin affinity column, elute, and then detect	Samples with extremely high interference (e.g., CAR-T cell supernatant)	High cost, only used in the R&D stage

Interference Verification Test

Interference verification must be carried out before the detection of all biopharmaceuticals to ensure the effectiveness of pretreatment. The steps are as follows:

1. Prepare the sample group: The test sample without pretreatment;

2. Prepare the spiked group: Add endotoxin of a known concentration (e.g., 0.1 EU/ml) to the test sample;

3. Detect the endotoxin concentrations of the two groups respectively, and calculate the recovery rate: Recovery rate = (Concentration of the spiked group - Concentration of the sample group) / Concentration of exogenously added endotoxin × 100%

4. Judgment standard: If the recovery rate is within the range of 50%-200%, it indicates no interference; otherwise, the pretreatment method needs to be optimized.

Detection Implementation Plan (Taking the Detection of Monoclonal Antibodies by Kinetic Chromogenic Method as an Example)

(1) Preparation Before Detection

1. Sample Preparation: Take a 100 mg/ml monoclonal antibody sample and dilute it to 50 mg/ml with LAL Reagent Water;

2. Reagent Preparation: BETMAT KCA Endotoxin Assay Kit (Kinetic Chromogenic Method) 300 Tests/kit, catalog number KCA300TB. The kit includes: Chromogenic LAL Reagent, Reconstitution Buffer, Control Standard Endotoxin, LAL Reagent Water;

3. Instrument Preparation: ① Kinetic Incubating Microplate Reader ELx808IUBET, catalog number: 808IUBET; ② Endotoxin-free glass dilution tubes; ③ Pipettors with endotoxin-free tips; ④ Endotoxin-free 96-well microplates; ⑤ Vortex mixer; ⑥ Test tube rack.

(2) Detection Steps

Preparation of Standard Curve
1. Dilute the endotoxin standard with LAL Reagent Water to a series of concentrations of 0.001, 0.01, 0.1, 1, and 10 EU/ml;
2. Add 100 μl of the standard to each well of the 96-well plate, with 3 parallel wells set for each concentration;
3. Add 100 μl of chromogenic LAL Reagent to each well;
4. Place the plate in the Incubating Microplate Reader and incubate at 37°C for 120 minutes. Measure the change in absorbance at 405 nm, reading the OD405nm every 30 seconds, and constructed the standard curve (R² ≥ 0.99).

Sample Detection
1. Add 100 μl of the diluted monoclonal antibody sample to the detection wells (2 parallel wells + 2 blank control wells set);
2. Repeat the incubation and reading steps of the standard curve;
3. Calculate the endotoxin concentration of the sample according to the standard curve, and multiply by the dilution factor to obtain the original concentration.

Interference Verification
1. The recovery rate of the spiked group (sample + 0.1 EU/ml endotoxin) is 85%, which meets the requirement of 50%-200%, so it is determined that there is no interference.

Result Judgment and Reporting

1. Judgment Standard: If the endotoxin concentration of the sample is ≤ the limit (e.g., monoclonal antibodies ≤ 1 EU/mg) and the interference verification is qualified, the sample is judged as "qualified";

2. Core Content of the Report: The "pretreatment method" and "interference verification result" should be indicated.

Quality Control and Risk Management

(I) Key Points of Laboratory Quality Control (QC)

Reagent Quality Control
1.For each new batch of reagents, "sensitivity verification (gel-clot method)" or "standard curve validity verification (photometric method or rFC method)" should be conducted: Use the standard to detect the actual sensitivity of the reagent, which should be consistent with the instruction manual;
2.When the sample may contain interfering substances such as glucan, the "specificity" of the reagent should be verified: Add interfering substances such as glucan and confirm that there is no false positive reaction.

Operation Process Control
1. Set up "Positive Control (PC)" and "Negative Control (NC)":
● PC: Endotoxin standard (to ensure the effectiveness of the reagent);
● NC: LAL Reagent Water (to ensure no cross-contamination);
2. The relative deviation of parallel samples should be ≤ 10% (stricter than the 15% standard for pharmaceutical water).

Instrument Calibration
● The microplate reader should be calibrated once a year (wavelength and absorbance accuracy);
● The pipette should be calibrated once a quarter (volume error ≤ 5%).

(II) Production Process Risk Management

1. Raw Material Control: The endotoxin of raw materials such as culture medium, serum, and purification column should be detected, with a limit of ≤ 0.01 EU/ml;

2. Process Control: Add an "endotoxin removal step" in the purification process (e.g., anion exchange chromatography, endotoxin adsorption affinity chromatography);

3. Environmental Control: The endotoxin in the air of the Grade A area (filling area) of the production workshop should be ≤ 0.03 EU/m³, and regular monitoring should be conducted.

Common Problems and Solutions

Common Problem	Root Cause	Solution
Poor linearity of the standard curve	Insufficient mixing when diluting the endotoxin standard	When diluting the endotoxin working standard, use a vortex mixer to mix for more than 30 seconds at each step
Poor repeatability of detection results	Uneven sample (endotoxin adsorbed on the protein surface)	Before detection, incubate the sample in a 60°C water bath for 10 minutes and vortex mix (avoid high temperature damaging the endotoxin)
Recovery rate lower than 50%	Failure to eliminate interference	Further dilute the sample and use a high-sensitivity chromogenic reagent, or adopt a pretreatment method combining dilution and sample heating

Project Optimization and Future Trends

Methodology Integration
Combine "kinetic chromogenic method for monitoring in the production process" with "gel-clot method for final product release detection" to balance efficiency and compliance;
Popularization of Animal-Derived-Free Methods
2.Adopt the rFC method to replace the traditional LAL method, in line with animal protection and sustainable development requirements.

Through the three-layer design of "method compatibility - interference elimination - strict quality control", this solution specifically addresses the core pain points of endotoxin detection in biopharmaceuticals, and can meet the detection needs throughout the whole life cycle from R&D, production to registration, providing key quality assurance for the safety of biopharmaceuticals.

Endotoxin Detection Solutions for Biopharmaceuticals